Quest, Vermillion Begin U.S. Marketing Push For Ovarian Cancer Test
This article was originally published in The Gray Sheet
Executive Summary
Quest Diagnostics will leverage its know-how of the women's health care segment and relationships with OB/GYNs to market Vermillion's OVA1, the first FDA-cleared blood test to help assess potentially malignant ovarian tumors prior to surgery